Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “V600-mutated BRAF Unresectable Melanoma”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Early research (Phase 1)UnknownNCT05103891
What this trial is testing

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Who this might be right for
MelanomaBRAF V600 MutationUnresectable Melanoma+1 more
Pierre Fabre Medicament 14
Early research (Phase 1)Active Not RecruitingNCT04913285
What this trial is testing

Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Who this might be right for
Solid Tumor, AdultNon-small Cell Lung CancerMelanoma
Pierre Fabre Medicament 400
Testing effectiveness (Phase 2)Ended earlyNCT01942993
What this trial is testing

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Who this might be right for
Melanoma
Philip Friedlander 3
Not applicableStudy completedNCT01990248
What this trial is testing

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 339
Early research (Phase 1)Study completedNCT01910181
What this trial is testing

Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 46
Early research (Phase 1)WithdrawnNCT04759846
What this trial is testing

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Who this might be right for
BRAF V600 MutationUnresectable MelanomaMetastatic Melanoma+1 more
Pierre Fabre Medicament
Early research (Phase 1)Study completedNCT05810740
What this trial is testing

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Who this might be right for
MelanomaBRAF V600 MutationUnresectable Melanoma+1 more
Pierre Fabre Medicament 37
Early research (Phase 1)Ended earlyNCT01611675
What this trial is testing

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 3
Early research (Phase 1)Active Not RecruitingNCT02721459
What this trial is testing

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Who this might be right for
MelanomaSkin Cancer
H. Lee Moffitt Cancer Center and Research Institute 26
Early research (Phase 1)Ended earlyNCT01826448
What this trial is testing

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Who this might be right for
V600-mutated BRAF Unresectable MelanomaV600-mutated BRAF Metastatic MelanomaStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
Daiichi Sankyo 13
Not applicableStudy completedNCT03663647
What this trial is testing

Advanced Melanoma in Russian Experience

Who this might be right for
Cutaneous Melanoma, Stage IVBRAF V600 Mutation
MelanomaPRO, Russia 382
Testing effectiveness (Phase 2)Active Not RecruitingNCT03235245
What this trial is testing

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Who this might be right for
Unresectable Stage III MelanomaStage IV Melanoma
European Organisation for Research and Treatment of Cancer - EORTC 271
Large-scale testing (Phase 3)Ended earlyNCT02967692
What this trial is testing

The Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 568
Not applicableStudy completedNCT04911998
What this trial is testing

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Who this might be right for
Melanoma (Skin)Metastatic MelanomaBRAF V600 Mutation
Pierre Fabre Medicament 400